NASS 2019 Annual Meeting

NanoBone Bone Graft harnesses the body’s capacity to heal bone and is an effective standalone grafting material. NanoBone consists of nanocrystals of hydroxyapatite, bioidentical to human bone, in a silica gel matrix. Upon implantation, NanoBone triggers angiogenesis, enhancing the differentiation of bone forming cells and stimulating new bone formation. It is highly nanoporous, providing 40X greater surface area for binding autologous growth factors including BMP-2 critical to new bone formation. In 10-15 days, NanoBone is replaced by an autologous osteogenic matrix and the normal process of cell-mediated bone formation and resorption proceeds until completely converted to autologous bone. 

NanoBone has been used successfully for more than ten years in Europe and the US in more than 100,000 clinical cases. In a prospective study, bone healing with NanoBone Bone Graft used alone was comparable to autograft with a lower complication rate. This is the same standard that growth factor products use to secure FDA approval and is in contrast to cellular allografts which are not required to demonstrate equivalency to autograft.